The Continuous Education Institute of the University of Barcelona (IL3) has invited Dr. Insa to lecture on drug repurposing in rare diseases. The event took place on July 10th in the summer university course titled “Rare diseases. From diagnostics to treatment” Course "Enfermedades raras. Del diagnóstico a la terapia" (ub.edu)

The current issue of The Brazilian Journal of Implantology and Health Sciences (Volume 6, Issue 6 (2024), Page 1040-105) cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.

Barcelona, Spain. March 12, 2024. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.…